Drug makers may be held liable for a "false marking" claim under a federal whistleblower law for printing expired patent numbers on product packages even when they have submitted accurate patent expiration dates for publication by the FDA, a federal judge has ruled.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *